Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Translational Cancer Research|February 4, 2022
Identification of biomarkers in colon cancer based on bioinformatic analysisYing Zhu, Leitao Sun, Jieru Yu, et al.
Frontiers in Oncology|March 15, 2021
Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical TrialsLeyin Zhang, Leitao Sun, Yiwen Zhou, et al.
Integrative Cancer Therapies|November 26, 2020
Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 InhibitorFeiyu Shan, Leitao Sun, Leyin Zhang, et al.
Medicine|September 15, 2018
Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer: A meta-analysisQingying Yan, Kaibo Guo, Guan Feng, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|July 26, 2019
Jiedu Sangen Decoction Inhibits the Invasion and Metastasis of Colorectal Cancer Cells by Regulating EMT through the Hippo Signaling PathwayLi Yuan, Mengmeng Zhou, Harpreet S Wasan, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|April 25, 2025
Bioactive components of Jiedu Sangen decoction against colorectal cancer: A novel and comprehensive research strategy for natural drug developmentXueer Zheng, Chao Shi, Ying Xie, et al.
Molecular Medicine Reports|September 17, 2019
Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial‑ mesenchymal transition via the AKT/GSK‑3β/Snail signaling pathwayLi Yuan, Mengmeng Zhou, Dawei Huang, et al.
Molecular Medicine Reports|October 12, 2022
[Corrigendum] Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial‑mesenchymal transition via the AKT/GSK‑3β/Snail signaling pathwayLi Yuan, Mengmeng Zhou, Dawei Huang, et al.
Scientific Reports|February 9, 2020
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysisLeitao Sun, Leyin Zhang, Jieru Yu, et al.
Biomed Research International|June 20, 2019
Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-AnalysisLeyin Zhang, Leitao Sun, Jieru Yu, et al.
Pageof 4